GKOS - Glaukos Corp Stock Price, Fair Value and News

$150.97+7.23 (+5.03%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GKOS Price Action

Last 7 days

8.7%

Last 30 days

6.7%

Last 90 days

18.2%

Trailing 12 Months

77.4%

GKOS RSI Chart

GKOS Valuation

Market Cap

8.3B

Price/Earnings (Trailing)

-55.65

Price/Sales (Trailing)

23.1

EV/EBITDA

-64.32

Price/Free Cashflow

-102.37

GKOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GKOS Fundamentals

GKOS Revenue

Revenue (TTM)

360.3M

Rev. Growth (Yr)

23.86%

Rev. Growth (Qtr)

1.02%

GKOS Earnings

Earnings (TTM)

-149.6M

Earnings Growth (Yr)

29.68%

Earnings Growth (Qtr)

57.64%

GKOS Profitability

EBT Margin

-41.24%

Return on Equity

-22.37%

Return on Assets

-16.14%

Free Cashflow Yield

-0.98%

GKOS Investor Care

Shares Dilution (1Y)

12.99%

Diluted EPS (TTM)

-2.96

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	326.4M	341.7M	360.3M	0
2023	289.1M	296.8M	303.6M	314.7M
2022	293.7M	288.3M	284.9M	282.9M
2021	237.6M	284.1M	294.0M	294.0M
2020	238.3M	211.3M	217.6M	225.0M
2019	195.2M	210.6M	225.2M	237.0M
2018	163.5M	165.4M	168.9M	181.3M
2017	127.2M	139.9M	150.8M	159.3M
2016	80.1M	90.9M	101.5M	114.4M
2015	52.0M	58.7M	65.5M	71.7M
2014	27.1M	33.3M	39.4M	45.6M
2013	0	0	0	20.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Glaukos Corp

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.

CEO	Mr. Thomas William Burns
WEBSITE	glaukos.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	783

Glaukos Corp Frequently Asked Questions

What is the ticker symbol for Glaukos Corp? What does GKOS stand for in stocks?

GKOS is the stock ticker symbol of Glaukos Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Glaukos Corp (GKOS)?

As of Fri Dec 20 2024, market cap of Glaukos Corp is 8.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GKOS stock?

You can check GKOS's fair value in chart for subscribers.

Is Glaukos Corp a good stock to buy?

The fair value guage provides a quick view whether GKOS is over valued or under valued. Whether Glaukos Corp is cheap or expensive depends on the assumptions which impact Glaukos Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GKOS.

What is Glaukos Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, GKOS's PE ratio (Price to Earnings) is -55.65 and Price to Sales (PS) ratio is 23.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GKOS PE ratio will change depending on the future growth rate expectations of investors.